Compare C3.ai Inc (AI) vs Pfizer Inc (PFE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
C3.ai Inc vs Pfizer Inc — how do they compare? C3.ai Inc trades at $8.84 (market cap $1.39B), while Pfizer Inc trades at $24.26 (market cap $137.19B). The key difference: Pfizer Inc is far larger — about 98.7× C3.ai Inc's market cap, and Pfizer Inc pays a 7.15% dividend while C3.ai Inc pays none. Which is the better fit depends on your goals.
| AI | PFE | |
|---|---|---|
Market Cap | $1.39B | $137.19B |
Sector | Technology | Health |
52-Week High | $29.16 | $28.56 |
52-Week Low | $7.76 | $23.29 |
Enterprise Value | $818.29M | $187.84B |
Volume | — | 29,869,932 |
Dividend Yield | — | 7.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai trades at $8.93, down 1.43% with bearish technical signals. The company shows revenue growth to $389M in 2025 but continues significant losses with -$289M net income. Analyst sentiment is mixed with 21% buy ratings and consensus target of $10.20. Recent developments include board member Jim Hagemann Snabe's appointment as European Commission Special Envoy for Industrial AI.
While revenue growth presents opportunity, persistent losses and negative cash flow pose substantial risk. The stock faces headwinds from unprofitability despite beating some earnings estimates. Upside potential exists if the company can accelerate path to profitability amid growing enterprise AI adoption.
Pfizer (PFE) trades at $23.72, down 2.47% on the day, with a bearish technical signal from moving averages but recent earnings beats. The stock has a P/E of 18.11 and net income margin of 11.83%, supported by strong cash flow from operations of $11.70B in 2025. Recent news highlights pipeline progress in obesity and oncology, with dividends of $0.43 paid semi-annually.
The outlook is mixed: analyst consensus is a 'Hold' with a $27.63 price target, implying potential upside, but risks include patent cliffs and competitive pressures. Revenue has declined from pandemic peaks, yet cost controls sustain profitability. Investors may find value if pipeline catalysts materialize, though near-term volatility persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
